Forecast of the MMSE score up to 6 years ahead, with cross-cohort replications

Most of the studies that focus on the Alzheimer’s disease (AD) prediction forecast a dementia label: cognitively normal, mild cognitive impairments or AD. However, these labels cannot always be compared across cohorts, they are not perfectly accurate and they describe the disease thanks to a limited number of stages (only 3) contrary to what is, in practice, a continuous progression. For these reasons, we predict the Mini-Mental State Examination (MMSE), a cognitive test whose scale presents 30 discrete values. Predicting this measure, assessed in multiple AD-related cohorts, allows better staging of the disease progression at the individual level, in particular in the ADNI, AIBL and PharmaCOG cohorts.